Navigation Links
Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments

Addiction can lead to hospitalization and drug withdrawal

CHICAGO, May 15, 2007 /PRNewswire/ -- A new survey of hundreds of migraine patients and physicians commissioned by the National Headache Foundation and conducted by Harris Interactive shows that 20 percent of migraine patients are currently taking potentially addictive medications that contain barbiturates or opioids and have not been approved by the U.S. Food and Drug Administration for the relief of migraines.

Migraines affect nearly 30 million Americans, according to the National Headache Foundation.

The survey also shows that patients taking prescription medications not approved by the FDA to treat migraines are more likely to experience drug-related side effects than patients taking prescription medications that have been approved by the FDA as migraine treatments.

"It's important for physicians, especially primary care physicians, who most often treat migraine patients, to be aware that medications containing opioids or barbiturates have the potential to produce drug dependence and addictive behavior, especially with regular use," said Richard B. Lipton, M.D., professor and vice chair of neurology at the Albert Einstein College of Medicine in New York City and director of the Montefiore Headache Center. "FDA-approved medications such as triptans are specifically targeted to treat migraine pain and associated symptoms and have a far better safety profile."

The survey of 502 patients and 201 primary care physicians and neurologists conducted earlier this year found that 53 percent of migraine patients take triptans as the primary prescription medication for their condition, but 20 percent take barbiturates or opioids. Another 27 percent take other medications.

Not All Migraine Treatments Are Equal

Triptans stop a migraine attack after the attack begins by stimulating serotonin, which reduces inflammation and
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
2. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
3. NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both Traditional and Non-traditional Migraine Symptoms
6. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks
7. Addex Reports Positive Results in Phase IIa Clinical Trial With ADX10059 in Migraine
8. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/31/2014)... , July 31, 2014  Today, ... a new extension to its PageCenterX ® ... software is designed to provide downtime reporting capabilities ... outages. LRS is releasing the product for general ... environment, EMR applications experience outages for a variety ...
(Date:7/31/2014)... CITY, Calif. , July 31, 2014  Genomic Health, ... company will host a conference call and webcast on Thursday, ... second quarter 2014 financial results.  The call and webcast will ... market close. Conference Call Details To access the ... Time via phone, please dial (877) 303-7208 from ...
(Date:7/31/2014)... 31, 2014 Nutrastar International Inc. (OTCQB: NUIN; ... of premium branded consumer products, including commercially cultivated Cordyceps ... today announced the signing of its first distributor for ... to Hubei Province ... China . The contract with ...
Breaking Medicine Technology:LRS Announces Downtime Reporting Solution for Healthcare 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 3Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 4Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
... March 5 A study published by Deborah ... the Journal of Drugs in Dermatology ... resurfacing technologies, specifically, the SmartXide DOT(TM) laser. DOT utilizes ... for rapid healing, less downtime and profound results. Dr. ...
... Complications Reported With Coronary DeviceDOYLESTOWN, Pa., March 4 ... in February by completing the enrollment of 30 ... clinical trial for the vProtect(TM) Luminal Shield, conducted ... Shield successfully crossed all target lesions and was ...
Cached Medicine Technology:New Study Published in the Journal of Drugs in Dermatology Finds DOT Microablative CO2 Laser Optimum for Skin Rejuvenation 2Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield 2
(Date:7/31/2014)... Dulles, VA (PRWEB) July 31, 2014 The ... diverse group of supporters from11:00am-11:00pm on August 7th. Simply ... while you enjoy great food and beverages with friends and ... dreams and ambitions. His amazing passion and contagious optimism ... while maintaining a positive attitude in effort to pursue a ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 ... world’s first whirlpool bathtub, has launched a new and ... distributor customers alike. , The Jacuzzi Luxury Bath website ... mirrors the superior design and quality represented by the ... focus on product design and inspirational bathroom applications. “The ...
(Date:7/31/2014)... Dr. Jeff Drake at Drake Chiropractic is ... the area and he has really made a business out ... working with new and return patients to improve treatments, get ... in pain or experience daily suffering should definitely contact Dr. ... never visited Drake Chiropractic, Dr. Drake is offering a new ...
(Date:7/31/2014)... According to a new market research ... Geography (North America, Europe, Asia-Pacific, the Middle East, and ... navigation system market is estimated at $2.75 billion in ... 2019. The inertial navigation system market for defense segment ... expected to reach $3.33 billion by 2019. The inertial ...
(Date:7/31/2014)... 31, 2014 The “Nucleic Acid ... Reagent based, Magnetic bead based), Consumables & Instruments, ... RNA isolation), End users - Global Forecasts to ... drivers, restraints, challenges, opportunities, current market trends, and ... purification market along with the estimates and forecasts ...
Breaking Medicine News(10 mins):Health News:Don't Forget To Mention Never Give Up 26 Foundation 2Health News:Jacuzzi Luxury Bath Launches New and Improved Website 2Health News:Drake Chiropractic Offers Special to New Patients in Wichita 2Health News:Inertial Navigation System Market Worth $4.63 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Inertial Navigation System Market Worth $4.63 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Inertial Navigation System Market Worth $4.63 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Inertial Navigation System Market Worth $4.63 Billion by 2019 - New Report by MarketsandMarkets 5Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 4
... , , , ... e-Zassi.com(TM), an online decision support software system, integrated business ... has partnered with Medical Development Group (MDG), a medical device ... agreement, MDG will provide access to the e-Zassi platform to ...
... Aug. 12 Hank Oprinski, the CEO at Cap ... tour to inform corporations, chambers of commerce, golfing communities, economic clubs, universities ... , What did all the following businessmen have ... Tiger Woods) , Merv Griffin (TV Producer) , Tom Witter (Dean/Witter/Reynolds) , ...
... , , , ... today that its CardioVasc Advantage(TM) Vascular Reconstruction Device has been ... , "The technology of the Advantage VRD ... noted company Chairman, Eric P. Milledge. "The technical platform behind ...
... , , , ... create expensive home health care costs. Poorly designed mobility aids or ... issue only part of the need is addressed which creates mobility ... alleviated if mobility issues were detected and properly addressed. , ...
... , , LONDON, Aug. ... optimal and efficient way and, at the same time, adhere ... pharmacovigilance tools and technologies. , , (Logo: ... Frost & Sullivan ( http://www.healthcareIT.frost.com ), World Pharmacovigilance Markets ...
... ... A GPS navigation device allows you to most accurately ... above the Earth’s surface - instantly. This multi-perspective triangulation clearly leads ... performance measurement system incorporates a number of key vital signs from ...
Cached Medicine News:Health News:Medical Development Group Partners with e-Zassi.com(TM) to Provide Members Access to Exciting New Software Tool 2Health News:Medical Development Group Partners with e-Zassi.com(TM) to Provide Members Access to Exciting New Software Tool 3Health News:September is Prostate Cancer Awareness Month 2Health News:Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device 2Health News:Expensive Health Care: Undetected, Unmet Mobility Needs Creating Boomer & Senior Health Care Costs 2Health News:Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 2Health News:Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 3Health News:Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance 2Health News:Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance 3
... MDS display system provides maximum impact for ... This unique approach to displaying frames allows ... and create appealing, flexible and eye-catching displays. ... and your patients are motivated. Removable holders. ...
A pre-assembled, hexagonal, revolving tower display with two round 19.75" in diameter adjustable shelves. Enjoy 3.5 square feet of elegant shelf space for your products....
A pre-assembled, rectangular shadow box/wall hanging display. It have 3 adjustable shelves with tempered glass, four 50 watt halogen top lights, laminated deck, dust resistant and electrical cord wit...
Classic is proud to provide top-quality vision eyewear to physicians, health maintenance organizations (HMOs), and numerous state and federal government programs. Classic Laboratory produces over 150...
Medicine Products: